Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Journal: American journal of clinical dermatology
Published: May 01, 2024
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age.
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age.
Journal: The journal of allergy and clinical immunology. In practice
Published: April 30, 2024
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure.
Journal: Clinical pharmacology in drug development
Published: February 29, 2024
Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 26, 2023
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Journal: American journal of clinical dermatology
Published: July 20, 2023
Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib.
Journal: Modern rheumatology
Published: July 18, 2023
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Journal: American journal of clinical dermatology
Published: August 17, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
Journal: Dermatology and therapy
Published: April 14, 2022
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Journal: Lancet (London, England)
Published: April 01, 2022
Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
Journal: Clinical pharmacokinetics
Published: February 18, 2022
Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 31, 2022
Last Updated: 09/26/2026